{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:26:01Z","timestamp":1788305161154,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170189"],"award-info":[{"award-number":["82170189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021YQ51"],"award-info":[{"award-number":["ZR2021YQ51"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Technology Development Project of Jinan City"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41375-025-02647-x","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T02:41:09Z","timestamp":1748313669000},"page":"1972-1986","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells"],"prefix":"10.1038","volume":"39","author":[{"given":"Shi","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Elsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Mendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Haughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Krenitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Plantevin-Krenitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0698-6433","authenticated-orcid":false,"given":"Weilin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-716X","authenticated-orcid":false,"given":"Xiangxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2647_CR1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-Hodgkin lymphomas. Lancet. 2024;403:1791\u2013807.","journal-title":"Lancet"},{"key":"2647_CR2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood.2020006783","volume":"138","author":"DM Stephens","year":"2021","unstructured":"Stephens DM, Byrd JC. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood. 2021;138:1099\u2013109.","journal-title":"Blood"},{"key":"2647_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13045-024-01533-w","volume":"17","author":"G Zhong","year":"2024","unstructured":"Zhong G, Kong R, Feng S, Wang C, Hao Q, Xie W, et al. Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting. J Hematol Oncol. 2024;17:14.","journal-title":"J Hematol Oncol"},{"key":"2647_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41571-021-00479-z","volume":"18","author":"M Jan","year":"2021","unstructured":"Jan M, Sperling AS, Ebert BL. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat Rev Clin Oncol. 2021;18:401\u201317.","journal-title":"Nat Rev Clin Oncol"},{"key":"2647_CR5","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.chembiol.2021.04.009","volume":"28","author":"Z Kozicka","year":"2021","unstructured":"Kozicka Z, Thoma NH. Haven\u2019t got a glue: Protein surface variation for the design of molecular glue degraders. Cell Chem Biol. 2021;28:1032\u201347.","journal-title":"Cell Chem Biol"},{"key":"2647_CR6","doi-asserted-by":"crossref","unstructured":"Goldhirsh G, Kravtsova-Ivantsiv Y, Satish G, Ziv T, Brik A, Ciechanover A. A short binding site in the KPC1 ubiquitin ligase mediates processing of NF-kappaB1 p105 to p50: a potential for a tumor-suppressive PROTAC. Proc Natl Acad Sci USA. 2021;118:e2117254118.","DOI":"10.1073\/pnas.2117254118"},{"key":"2647_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong G, Chang X, Xie W, Zhou X. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther. 2024;9:308.","journal-title":"Signal Transduct Target Ther"},{"key":"2647_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN. Br J Haematol. 2014;164:811\u201321.","journal-title":"Br J Haematol"},{"key":"2647_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301\u20135.","journal-title":"Science"},{"key":"2647_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100971","volume":"56","author":"R Drula","year":"2022","unstructured":"Drula R, Iluta S, Gulei D, Iuga C, Dima D, Ghiaur G, et al. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. Blood Rev. 2022;56:100971.","journal-title":"Blood Rev"},{"key":"2647_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21:803\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"2647_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kronke","year":"2015","unstructured":"Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523:183\u20138.","journal-title":"Nature"},{"key":"2647_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold G, Fischer ES, Thoma NH. Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase. Nature. 2016;532:127\u201330.","journal-title":"Nature"},{"key":"2647_CR14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/17460441.2019.1660641","volume":"14","author":"JC Groppe","year":"2019","unstructured":"Groppe JC. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy. Expert Opin Drug Discov. 2019;14:1237\u201353.","journal-title":"Expert Opin Drug Discov"},{"key":"2647_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","volume":"100","author":"R Roskoski Jr","year":"2015","unstructured":"Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1\u201323.","journal-title":"Pharmacol Res"},{"key":"2647_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314\u201322.","journal-title":"Nat Rev Cancer"},{"key":"2647_CR17","doi-asserted-by":"crossref","unstructured":"Martinez-Valbuena I, Lee S, Santamaria E, Irigoyen JF, Forrest S, Li J, et al. 4R-Tau seeding activity unravels molecular subtypes in patients with progressive supranuclear Palsy. bioRxiv. 2023.","DOI":"10.1101\/2023.09.28.559953"},{"key":"2647_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-020-00906-1","volume":"13","author":"X Zhou","year":"2020","unstructured":"Zhou X, Chen N, Xu H, Zhou X, Wang J, Fang X, et al. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. J Hematol Oncol. 2020;13:77.","journal-title":"J Hematol Oncol"},{"key":"2647_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s11658-023-00445-w","volume":"28","author":"X Chen","year":"2023","unstructured":"Chen X, Lu T, Cai Y, Han Y, Ding M, Chu Y, et al. KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway. Cell Mol Biol Lett. 2023;28:32.","journal-title":"Cell Mol Biol Lett"},{"key":"2647_CR20","doi-asserted-by":"publisher","first-page":"32384","DOI":"10.1074\/jbc.M109.052647","volume":"284","author":"AS Huart","year":"2009","unstructured":"Huart AS, MacLaine NJ, Meek DW, Hupp TR. CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem. 2009;284:32384\u201394.","journal-title":"J Biol Chem"},{"key":"2647_CR21","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.1128\/MCB.25.15.6509-6520.2005","volume":"25","author":"L Chen","year":"2005","unstructured":"Chen L, Li C, Pan Y, Chen J. Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol Cell Biol. 2005;25:6509\u201320.","journal-title":"Mol Cell Biol"},{"key":"2647_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1084\/jem.20131033","volume":"211","author":"M J\u00e4r\u00e5s","year":"2014","unstructured":"J\u00e4r\u00e5s M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014;211:605\u201312.","journal-title":"J Exp Med"},{"key":"2647_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1126\/science.1090769","volume":"302","author":"AA Ruefli-Brasse","year":"2003","unstructured":"Ruefli-Brasse AA, French DM, Dixit VM. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science. 2003;302:1581\u20134.","journal-title":"Science"},{"key":"2647_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.immuni.2006.10.010","volume":"25","author":"J Schulze-Luehrmann","year":"2006","unstructured":"Schulze-Luehrmann J, Ghosh S. Antigen-receptor signaling to nuclear factor kappa B. Immunity. 2006;25:701\u201315.","journal-title":"Immunity"},{"key":"2647_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature07613","volume":"458","author":"N Bidere","year":"2009","unstructured":"Bidere N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, et al. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature. 2009;458:92\u201396.","journal-title":"Nature"},{"key":"2647_CR26","doi-asserted-by":"publisher","first-page":"re13","DOI":"10.1126\/stke.3572006re13","volume":"2006","author":"H H\u00e4cker","year":"2006","unstructured":"H\u00e4cker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;2006:re13.","journal-title":"Sci STKE"},{"key":"2647_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/25159","volume":"396","author":"A Yaron","year":"1998","unstructured":"Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, et al. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature. 1998;396:590\u20134.","journal-title":"Nature"},{"key":"2647_CR28","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.celrep.2019.09.040","volume":"29","author":"T Gehring","year":"2019","unstructured":"Gehring T, Erdmann T, Rahm M, Grass C, Flatley A, O\u2019Neill TJ, et al. MALT1 phosphorylation controls activation of T lymphocytes and survival of ABC-DLBCL tumor cells. Cell Rep. 2019;29:873\u201388.e810.","journal-title":"Cell Rep"},{"key":"2647_CR29","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1242\/jcs.069476","volume":"123","author":"G Carvalho","year":"2010","unstructured":"Carvalho G, Le Guelte A, Demian C, Vazquez A, Gavard J, Bid\u00e8re N. Interplay between BCL10, MALT1 and IkappaBalpha during T-cell-receptor-mediated NFkappaB activation. J Cell Sci. 2010;123:2375\u201380.","journal-title":"J Cell Sci"},{"key":"2647_CR30","doi-asserted-by":"publisher","first-page":"a000109","DOI":"10.1101\/cshperspect.a000109","volume":"2","author":"LM Staudt","year":"2010","unstructured":"Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2:a000109.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2647_CR31","doi-asserted-by":"publisher","first-page":"E7230","DOI":"10.1073\/pnas.1507459112","volume":"112","author":"N Knies","year":"2015","unstructured":"Knies N, Alankus B, Weilemann A, Tzankov A, Brunner K, Ruff T, et al. Lymphomagenic CARD11\/BCL10\/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kappaB and JNK activation. Proc Natl Acad Sci USA. 2015;112:E7230\u201338.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2647_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689472","volume":"12","author":"CIE Smith","year":"2021","unstructured":"Smith CIE, Burger JA. Resistance mutations to BTK inhibitors originate from the NF-kappaB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway. Front Immunol. 2021;12:689472.","journal-title":"Front Immunol"},{"key":"2647_CR33","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1126\/science.1153629","volume":"319","author":"G Lenz","year":"2008","unstructured":"Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319:1676\u20139.","journal-title":"Science"},{"key":"2647_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","volume":"10","author":"V Tisato","year":"2017","unstructured":"Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. J Hematol Oncol. 2017;10:133.","journal-title":"J Hematol Oncol"},{"key":"2647_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.tcb.2010.01.009","volume":"20","author":"M Wade","year":"2010","unstructured":"Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010;20:299\u2013309.","journal-title":"Trends Cell Biol"},{"key":"2647_CR36","doi-asserted-by":"publisher","first-page":"12009","DOI":"10.1073\/pnas.2030930100","volume":"100","author":"LK Linares","year":"2003","unstructured":"Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA. 2003;100:12009\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2647_CR37","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1002\/j.1460-2075.1996.tb00919.x","volume":"15","author":"A Shvarts","year":"1996","unstructured":"Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996;15:5349\u201357.","journal-title":"EMBO J"},{"key":"2647_CR38","doi-asserted-by":"publisher","first-page":"12941","DOI":"10.1074\/jbc.M115.644435","volume":"290","author":"PL Leslie","year":"2015","unstructured":"Leslie PL, Ke H, Zhang Y. The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization. J Biol Chem. 2015;290:12941\u201350.","journal-title":"J Biol Chem"},{"key":"2647_CR39","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1128\/MCB.00851-12","volume":"32","author":"S Wu","year":"2012","unstructured":"Wu S, Chen L, Becker A, Schonbrunn E, Chen J. Casein kinase 1alpha regulates an MDMX intramolecular interaction to stimulate p53 binding. Mol Cell Biol. 2012;32:4821\u201332.","journal-title":"Mol Cell Biol"},{"key":"2647_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-018-0087-2","volume":"19","author":"J Ruland","year":"2019","unstructured":"Ruland J, Hartjes L. CARD-BCL-10-MALT1 signalling in protective and pathological immunity. Nat Rev Immunol. 2019;19:118\u201334.","journal-title":"Nat Rev Immunol"},{"key":"2647_CR41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.immuni.2005.10.007","volume":"23","author":"R Matsumoto","year":"2005","unstructured":"Matsumoto R, Wang D, Blonska M, Li H, Kobayashi M, Pappu B, et al. Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation. Immunity. 2005;23:575\u201385.","journal-title":"Immunity"},{"key":"2647_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.immuni.2005.09.014","volume":"23","author":"K Sommer","year":"2005","unstructured":"Sommer K, Guo B, Pomerantz JL, Bandaranayake AD, Moreno-Garcia ME, Ovechkina YL, et al. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity. 2005;23:561\u201374.","journal-title":"Immunity"},{"key":"2647_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.733848","volume":"11","author":"S Manni","year":"2021","unstructured":"Manni S, Fregnani A, Quotti Tubi L, Spinello Z, Carraro M, Scapinello G, et al. Protein Kinase CK1alpha Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. Front Oncol. 2021;11:733848.","journal-title":"Front Oncol"},{"key":"2647_CR44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.molimm.2014.01.011","volume":"59","author":"J Cheng","year":"2014","unstructured":"Cheng J, Hamilton KS, Kane LP. Phosphorylation of Carma1, but not Bcl10, by Akt regulates TCR\/CD28-mediated NF-kappaB induction and cytokine production. Mol Immunol. 2014;59:110\u20136.","journal-title":"Mol Immunol"},{"key":"2647_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-231","volume":"13","author":"B Schittek","year":"2014","unstructured":"Schittek B, Sinnberg T. Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis. Mol Cancer. 2014;13:231.","journal-title":"Mol Cancer"},{"key":"2647_CR46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307\u201310.","journal-title":"Nature"},{"key":"2647_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83\u201396.","journal-title":"Nat Rev Cancer"},{"key":"2647_CR48","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1146\/annurev-pathol-012414-040349","volume":"11","author":"O Karni-Schmidt","year":"2016","unstructured":"Karni-Schmidt O, Lokshin M, Prives C. The Roles of MDM2 and MDMX in Cancer. Annu Rev Pathol. 2016;11:617\u201344.","journal-title":"Annu Rev Pathol"},{"key":"2647_CR49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41392-023-01626-x","volume":"8","author":"Y Fang","year":"2023","unstructured":"Fang Y, Zhang MC, He Y, Li C, Fang H, Xu PP, et al. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8:381.","journal-title":"Signal Transduct Target Ther"},{"key":"2647_CR50","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","volume":"10","author":"TE Lew","year":"2023","unstructured":"Lew TE, Minson A, Dickinson M, Handunnetti SM, Blombery P, Khot A, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023;10:e142\u2013e154.","journal-title":"Lancet Haematol"},{"key":"2647_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","volume":"175","author":"W Minzel","year":"2018","unstructured":"Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, et al. Small molecules co-targeting CKIalpha and the transcriptional kinases CDK7\/9 control AML in preclinical models. Cell. 2018;175:171\u201385.e125.","journal-title":"Cell"},{"key":"2647_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44698-1","volume":"15","author":"G Nishiguchi","year":"2024","unstructured":"Nishiguchi G, Mascibroda LG, Young SM, Caine EA, Abdelhamed S, Kooijman JJ, et al. Selective CK1alpha degraders exert antiproliferative activity against a broad range of human cancer cell lines. Nat Commun. 2024;15:482.","journal-title":"Nat Commun"},{"key":"2647_CR53","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.ccell.2023.02.010","volume":"41","author":"SM Park","year":"2023","unstructured":"Park SM, Miyamoto DK, Han GYQ, Chan M, Curnutt NM, Tran NL, et al. Dual IKZF2 and CK1alpha degrader targets acute myeloid leukemia cells. Cancer Cell. 2023;41:726\u201339.e711.","journal-title":"Cancer Cell"},{"key":"2647_CR54","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2767-9764.CRC-23-0264","volume":"4","author":"D Kanaoka","year":"2024","unstructured":"Kanaoka D, Yamada M, Yokoyama H, Nishino S, Kunimura N, Satoyoshi H, et al. FPFT-2216, a novel anti-lymphoma compound, induces simultaneous degradation of IKZF1\/3 and CK1alpha to activate p53 and inhibit NFkappaB signaling. Cancer Res Commun. 2024;4:312\u201327.","journal-title":"Cancer Res Commun"},{"key":"2647_CR55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88\u201392.","journal-title":"Nature"},{"key":"2647_CR56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560:387\u201391.","journal-title":"Nature"},{"key":"2647_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","volume":"52","author":"RM Young","year":"2015","unstructured":"Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52:77\u201385.","journal-title":"Semin Hematol"},{"key":"2647_CR58","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","volume":"27","author":"DA Nalawansha","year":"2020","unstructured":"Nalawansha DA, Crews CM. PROTACs: an emerging therapeutic modality in precision medicine. Cell Chem Biol. 2020;27:998\u20131014.","journal-title":"Cell Chem Biol"},{"key":"2647_CR59","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li K, Crews CM. PROTACs: past, present and future. Chem Soc Rev. 2022;51:5214\u201336.","journal-title":"Chem Soc Rev"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02647-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02647-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02647-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:23:58Z","timestamp":1757179438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02647-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2647"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02647-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.X., J.E., D.M., M.H., P.K., V.P.K., P.P., and F.M. are currently employed by Innovo Therapeutics and currently hold stock options in a privately held company. This study did not receive funding from Innovo Therapeutics, and we declare that these relationships do not influence the study design, data analysis, or interpretation of results. The remaining authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Medical Ethical Committee of Shandong Provincial Hospital. All samples were obtained with informed consent in accordance with the Declaration of Helsinki. All animal experimental procedures were performed in accordance with the protocols approved by the Institutional Animal Care and Research Advisory Committee of Shandong Provincial Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}